Literature DB >> 21382306

Patient-level predictors and clinical correlates of duration of untreated psychosis among hospitalized first-episode patients.

Michael T Compton1, Tynessa L Gordon, Sandra M Goulding, Michelle L Esterberg, Tandrea Carter, Amy S Leiner, Paul S Weiss, Benjamin G Druss, Elaine F Walker, Nadine J Kaslow.   

Abstract

OBJECTIVE: Duration of untreated psychosis (DUP) has been associated with poor early course outcomes of nonaffective psychotic disorders; however, less is known about predictors of DUP. This study examined patient-level predictors of DUP and clinical correlates of both DUP and duration of untreated illness (DUI), both of which have been implicated as prognostic indicators.
METHOD: Participants included 109 first-episode patients hospitalized in 3 public-sector inpatient psychiatric units serving an urban, socially disadvantaged, predominantly African American community. DUP, DUI, and a number of clinical and psychosocial variables were measured using standardized methods. Patients were diagnosed with schizophrenia and related psychotic disorders according to the Structured Clinical Interview for DSM-IV Axis I Disorders.
RESULTS: The median DUP and DUI were 22.3 and 129.9 weeks, respectively. Survival analyses revealed that, at any given time point, patients not living with family members were, on average, about 1.5 times as likely to be hospitalized as those living with family when controlling for mode of onset of psychosis. Patients not living in poverty were, on average, about 1.6 times as likely to be hospitalized as those living in poverty when controlling for mode. A greater burden of negative symptoms was associated with longer DUP (r = 0.23, P = .02), and poorer insight was associated with longer DUI (r = -0.24, P = .01). Longer DUP and DUI were associated with diverse adverse clinical characteristics, such as greater impairment in global functioning, poorer social functioning, and more psychosocial problems.
CONCLUSIONS: There is a need for early intervention efforts to be directed to families (and their loved ones who live with them with emerging psychotic disorders or frank untreated psychotic syndromes), particularly families facing major socioeconomic challenges. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21382306     DOI: 10.4088/JCP.09m05704yel

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  22 in total

1.  Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis.

Authors:  Michael T Compton; Beth Broussard; Claire E Ramsay; Tarianna Stewart
Journal:  Schizophr Res       Date:  2010-10-30       Impact factor: 4.939

2.  Overview and initial validation of two detailed, multidimensional, retrospective measures of substance use: the Lifetime Substance Use Recall (LSUR) and Longitudinal Substance Use Recall for 12 Weeks (LSUR-12) Instruments.

Authors:  Claire E Ramsay; Glen R Abedi; John D Marson; Michael T Compton
Journal:  J Psychiatr Res       Date:  2010-05-20       Impact factor: 4.791

3.  Measuring insight through patient self-report: an in-depth analysis of the factor structure of the Birchwood Insight Scale.

Authors:  Sean D Cleary; Sanaa Bhatty; Beth Broussard; Sarah L Cristofaro; Claire Ramsay Wan; Michael T Compton
Journal:  Psychiatry Res       Date:  2014-02-06       Impact factor: 3.222

4.  Impaired insight in patients with newly diagnosed nonaffective psychotic disorders with and without deficit features.

Authors:  Hanan D Trotman; Brian Kirkpatrick; Michael T Compton
Journal:  Schizophr Res       Date:  2011-03       Impact factor: 4.939

5.  Subscale structure for the Positive and Negative Syndrome Scale (PANSS): a proposed solution focused on clinical validity.

Authors:  Mary E Kelley; Leonard White; Michael T Compton; Philip D Harvey
Journal:  Psychiatry Res       Date:  2012-09-10       Impact factor: 3.222

6.  Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders.

Authors:  Mary E Kelley; Claire Ramsay Wan; Beth Broussard; Anthony Crisafio; Sarah Cristofaro; Stephanie Johnson; Thomas A Reed; Patrick Amar; Nadine J Kaslow; Elaine F Walker; Michael T Compton
Journal:  Schizophr Res       Date:  2016-01-17       Impact factor: 4.939

7.  Family history of psychosis negatively impacts age at onset, negative symptoms, and duration of untreated illness and psychosis in first-episode psychosis patients.

Authors:  Michelle Esterberg; Michael Compton
Journal:  Psychiatry Res       Date:  2012-04-14       Impact factor: 3.222

8.  Demographic, socio-environmental, and substance-related predictors of duration of untreated psychosis (DUP).

Authors:  Beth Broussard; Mary E Kelley; Claire Ramsay Wan; Sarah L Cristofaro; Anthony Crisafio; Patrick J Haggard; Neely L Myers; Thomas Reed; Michael T Compton
Journal:  Schizophr Res       Date:  2013-06-06       Impact factor: 4.939

9.  Measuring trauma and stressful events in childhood and adolescence among patients with first-episode psychosis: initial factor structure, reliability, and validity of the Trauma Experiences Checklist.

Authors:  Sarah L Cristofaro; Sean D Cleary; Claire Ramsay Wan; Beth Broussard; Colby Chapman; Patrick J Haggard; Sara Jananeh; Neely L Myers; Michael T Compton
Journal:  Psychiatry Res       Date:  2013-07-11       Impact factor: 3.222

10.  Subtyping first-episode non-affective psychosis using four early-course features: potentially useful prognostic information at initial presentation.

Authors:  Michael T Compton; Mary E Kelley; Dawn F Ionescu
Journal:  Early Interv Psychiatry       Date:  2013-01-24       Impact factor: 2.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.